Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID‐19 patients: A systematic review and meta‐analysis

As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID‐19) is becoming clearer and the potential for immunotherapy is increasing. However, clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) treatment in COVID‐19 patients are...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Jingwen, Fu, Meihua, Mei, Huan, Zheng, Hailin, Liang, Guanzhao, She, Xiaodong, Wang, Qiong, Liu, Weida
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646369/
https://www.ncbi.nlm.nih.gov/pubmed/34558756
http://dx.doi.org/10.1002/rmv.2295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8646369/
https://www.ncbi.nlm.nih.gov/pubmed/34558756
http://dx.doi.org/10.1002/rmv.2295

Ejemplares similares